IP Library Patent Application 18703024
Patent Application
App. No. 18/703,024

Anhydrous Urea Emulsions with a Retinoid Agent

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/703,024
Abstract

Topical formulations of urea and a retinoid agent dissolved in a non-aqueous skin-compatible solvent and combined with organosilicone compounds into an emulsion are provided. The formulations are storage stable for an extended period of time without significant degradation of the urea or retinoid agent in the composition and have desirable physical properties. Topical compositions of this disclosure find use in treating or preventing a variety of cosmetic and/or dermatological conditions.

Claims (135)

1 . A storage stable topical emulsion composition comprising:

a. a dispersed phase that is a homogenous solution comprising:

1% to 30% by weight of urea agent;

dissolved in 10% or more by weight of a non-aqueous skin-compatible solvent selected from polyol, C (1-6) alkanediol, glycol ether, dimethyl ether, and a combination thereof; and

b. a continuous phase comprising:

0.01 to 1.5% of a retinoid agent; and

10% or more by composition weight of a silicone agent selected from cyclic, linear and branched silicones, a silicone crosspolymer, and a combination thereof,

 wherein the dispersed phase is immiscible with and contained within the continuous phase.

2 . The composition of claim 1 , further comprising an antioxidant.

3 . The composition of claim 2 , wherein the antioxidant is selected from ascorbic acid, and azelaic acid, and any combination thereof.

4 . The composition of claim 3 , wherein the composition comprises ascorbic acid.

5 . The composition of claim 4 , wherein the composition comprises 22% or less by weight of ascorbic acid dissolved in the dispersed phase or the continuous phase.

6 . The composition of claim 5 , wherein the composition comprises about 5% to 15% by weight of ascorbic acid dissolved in the dispersed phase or the continuous phase.

7 . The composition of claim 6 , wherein the composition comprises about 5% by weight of ascorbic acid dissolved in the dispersed phase or the continuous phase.

8 . The composition of any one of claims 3 to 7 , wherein the composition comprises azelaic acid.

9 . The composition of claim 8 , wherein the composition comprises 22% or less by weight of azelaic acid dissolved in the dispersed phase or the continuous phase.

10 . The composition of claim 9 , wherein the composition comprises about 5% to 15% by weight of azelaic acid dissolved in the dispersed phase or the continuous phase.

11 . The composition of claim 10 , wherein the composition comprises about 5% by weight of azelaic acid dissolved in the dispersed phase or the continuous phase.

12 . The composition of any one of claims 1 to 11 , wherein the composition comprises 0.015 to 1% by weight of retinoid agent.

13 . The composition of any one of claims 1 to 11 , wherein the composition comprises 0.02% by weight of retinoid agent.

14 . The composition of any one of claims 1 to 11 , wherein the composition comprises 0.5% by weight of ferulic acid.

15 . The composition of any one of claims 1 to 14 , wherein the retinoid agent is selected from retinol, a retinyl ester, retinal, tretinoin, isotretinoin, alitretinoin, etretinate, acitretin, adapalene, bexarotene and tazarotene.

16 . The composition of claim 15 , wherein the retinoid agent is retinol.

17 . The composition of claim 15 , wherein the retinoid agent is a retinyl ester (e.g., retinyl acetate, or retinyl propionate)

18 . The composition of claim 15 , wherein the retinoid agent is tretinoin.

19 . The composition of claim 15 , wherein the retinoid is adapalene or tararotene.

20 . The composition of claim any one of claims 1 to 19 , wherein the continuous phase is a solution of the silicone agent in an oil-phase.

21 . The composition of any one of claims 1 to 20 , wherein the silicone agent is selected from dimethicone, PEG-10/15 crosspolymer, dimethicone/polyethylene glycol (PEG)-10/15 crosspolymer, lauryl PEG-9 polydimethylsiloxyethyl dimethicone, and a combination thereof.

22 . The composition of any one of claims 1-21 , wherein the composition comprises 5 to 20% by weight of the silicone agent.

23 . The composition of any one of claims 1-22 , wherein the urea agent is urea.

24 . The composition of any one of claims 1-22 , wherein the urea agent is hydroxyethyl urea.

25 . The composition of any one of claims 1-24 , wherein the urea agent comprises a mixture of urea and hydroxyethyl urea.

26 . The composition of any one of claims 1-25 , wherein the non-aqueous solvent is selected from 1,3 propanediol, 1,2 propanediol, 1,3 butanediol, 1,5 pentanediol, 1,2 hexanediol, 1,6 hexanediol, glycerol, diglycerol, ethoxydiglycol, dimethyl isosorbide and a combination thereof.

27 . The composition of claim 26 , wherein the solvent is 1,3 propanediol.

28 . The composition of any one of claims 1-27 , wherein the composition exhibits a urea degradation rate that is less than the urea degradation rate of a homogenous dispersed phase solution in the absence of the continuous phase emulsion.

29 . The composition of any one of claims 1-28 , wherein the composition comprises 20% to 80% by weight of the silicone agent of the continuous phase.

30 . The composition of any one of claims 1-29 , wherein the composition comprises 5% to 20% by weight of the urea agent.

31 . The composition of any one of claims 1-30 , wherein the composition comprises 0.015% to 0.5% by weight of the retinoid agent.

32 . The composition of any one of claims 1-31 , wherein the percent by weight ratio of the dispersed phase to the continuous phase in the composition is 19 or less.

33 . The composition of any one of claims 1-32 , further comprising 10% or less by weight in total of one or more optional additional components dissolved in the dispersed and/or continuous phase (e.g., additional antioxidants, soothing agents, etc.).

34 . The composition of claim 33 , wherein the one or more optional additional components are selected from tocopherols, tocotrienols (e.g., alpha, beta, delta and gamma tocopherols or alpha, beta, delta and gamma tocotrienols), cinnamic acid, ferulic acid, hydroxy acids (e.g., salicylic acid), panthenol, Pinus pinaster bark extract, hyaluronic acid complex, cholesterol ester, cholesterol, ceramide, linoleic acid, linolenic acid, madecassoside, acetyl zingerone, bakuchiol, bis-ethylhexyl hydroxydimethoxy benzylmalonate, zinc oxide, and titanium dioxide

35 . The composition of any one of claims 1-34 , wherein the composition comprises about 5% to about 20% by weight of urea.

36 . The composition of any one of claim 35 , wherein the composition comprises about 5% by weight of urea.

37 . The composition of claim 36 , wherein the composition comprises about 10% by weight of urea.

38 . The composition of any one of claims 33 - 38 , wherein the optional additional component comprises ferulic acid.

39 . The composition of claim 34 , wherein the composition comprises 0.1% to 2% by weight of ferulic acid.

40 . The composition of any one of claims 1 to 39 , wherein the composition comprises 0.5% by weight of ferulic acid.

41 . The composition of any one of claims 33-40 , wherein the optional additional component comprises vitamin E.

42 . The composition of claim 41 , wherein the vitamin E is selected from alpha, beta, delta and gamma tocopherols and alpha, beta, delta and gamma tocotrienols, and combinations thereof.

43 . The composition of claim 41 or 42 , wherein the composition comprises 2% or less by weight of vitamin E.

44 . The composition of claim 33-43 , wherein the optional additional component is bis-ethylhexyl hydroxydimethoxy benzylmalonate.

45 . The composition of claim 44 , wherein the composition comprises 2% or less by weight of bis-ethylhexyl hydroxydimethoxy benzylmalonate.

46 . The composition of any one of claims 33-45 , wherein the optional additional component comprises bakuchiol.

47 . The composition of claim 46 , wherein the composition comprises 2% or less of bakuchiol.

48 . The composition of any one of claims 33-47 , wherein the optional additional component comprises C10-C30 cholesterol/lanosterol esters.

49 . The composition of claim 48 , wherein the composition comprises 5% or less of C10-C30 cholesterol/lanosterol esters.

50 . The composition of any one of claims 33-49 , wherein the optional additional component comprises madecassoside, asiaticoside, or a combination thereof.

51 . The composition of claim 50 , wherein the composition comprises 1% or less by weight of a combination of madecassoside and asiaticoside.

52 . The composition of any one of claims 33 - 52 , wherein the optional additional component comprises glycyrrhetinic acid.

53 . The composition of claim 52 , wherein the composition comprises 1% or less of glycyrrhetinic acid.

54 . The composition of any one of claims 33-53 , wherein the optional additional component comprises Pinus pinaster bark extract.

55 . The composition of claim 54 , wherein the composition comprises 0.5% to 2% by weight of Pinus pinaster bark extract.

56 . The composition of any one of claims 33-55 , wherein the optional additional component comprises a ceramide.

57 . The composition of claim 56 , wherein the ceramide is selected from ceramide EOP, ceramide AP, ceramide NG, ceramide NP, ceramide NS, ceramide EOS, ceramide S, ceramide AS, and combinations thereof.

58 . The composition of claim 57 , wherein the composition comprises 2% or less by weight of ceramide.

59 . The composition of any one of claims 33-58 , wherein the optional additional component comprises cholesterol.

60 . The composition of claim 59 , wherein the composition comprises less than 2% by weight of cholesterol.

61 . The composition of any one of claims 33-60 , wherein the optional additional component comprises a free fatty acid.

62 . The composition of claim 61 , wherein the free fatty acid is selected from linoleic acid, linolenic acid, stearic acid, palmitic acid, oleic acid, alpha-linoleic, oleic acid, and combinations thereof.

63 . The composition of claim 61 or 62 , wherein the composition comprises less than 1% free fatty acid.

64 . The composition of any one of claims 1 to 63 , wherein droplets of the dispersed phase are contained within the continuous phase.

65 . The composition of any one of claims 1-64 , wherein the composition comprises:

in the dispersed phase:

56% by weight of propanediol;

5% by weight of urea;

5% by weight of azelaic acid; and

5% by weight of ascorbic acid; and

in the continuous phase:

0.02% by weight of the retinoid agent.

66 . The composition of any one of claims 1-65 , wherein the composition comprises:

in the dispersed phase:

56% by weight of propanediol;

5% by weight of urea;

5% by weight of azelaic acid; and

5% by weight of ascorbic acid; and

in the continuous phase:

1% by weight of a combination of Allyl Methacrylate Crosspolymer, Polysorbate 20, Retinol and Tocopherol;

4% by weight of C10-30 cholesterol/lanosterol esters;

0.5% by weight of Bakuchiol;

1% by weight of Tocopherol; and

20% by weight of dimethicone and dimethicone/PEG-10/15 crosspolymer.

67 . The composition of any one of claims 1-65 , wherein the composition comprises:

in the dispersed phase:

56% by weight of propanediol;

5% by weight of urea;

5% by weight of azelaic acid; and

5% by weight of ascorbic acid; and

in the continuous phase:

0.2% by weight of the retinoid agent;

0.8% by weight of a combination of Allyl Methacrylate Crosspolymer, Polysorbate 20, and Tocopherol;

4% by weight of C10-30 cholesterol/lanosterol esters;

0.5% by weight of Bakuchiol;

1% by weight of Tocopherol; and

20% by weight of dimethicone and dimethicone/PEG-10/15 crosspolymer.

68 . A ready-to-use topical preparation in a multi-use container which is pre-filled with a storage stable topical composition according to any of the claims 1-67 , wherein the multi-use container comprises means for dispensing a single dose of the storage stable topical composition.

69 . The preparation of claim 68 , wherein the multi-use container is a time-release container that delivers urea and the retinoid agent consistently over a period of time.

70 . The preparation of claim 69 , wherein the time-release container does not release urea and the retinoid agent all at once.

71 . The preparation of any one of claims 68-70 , wherein the storage stable topical composition is sealed in the container.

72 . The preparation of any one of claims 68-63 , wherein the container is placed in packaging.

73 . A process for producing a storage stable emulsion composition for topical application, the process comprising:

a) combining:

i. 1% to 30% by weight of urea agent selected from urea, hydroxyethyl urea, and combination thereof;

ii. 10% to 80% by weight of a non-aqueous skin-compatible solvent selected from polyol, C (1-6) alkanediol, glycol ether, dimethyl ether, and a combination thereof; and

iii. optionally one or more additional agents;

 thereby dissolving the urea agent, and one or more additional agents in the non-aqueous solvent to produce a dispersed phase that is a homogenous solution; and

b) suspending the dispersed phase in a continuous phase comprising 10% or more by weight of a silicone compound dissolved in an oil-phase solution; and 0.01% to 1.5% of a retinoid agent;

to produce an emulsion composition that is storage stable.

74 . The process of claim 73 , wherein the silicone compound is selected from cyclic, linear and branched silicones, a silicone crosspolymer, and a combination thereof.

75 . The process of claim 73 or 74 , wherein the one or more additional agents comprise ascorbic acid.

76 . The process of claim 75 , wherein the dispersed phase comprises 22% or less by weight of ascorbic acid.

77 . The process of claim 76 , wherein the dispersed phase comprises about 5% to about 15% by weight of ascorbic acid.

78 . The process of any one of claims 73-77 , wherein the one or more additional agents comprise ferulic acid.

79 . The process of claim 78 , wherein the composition comprises 2% or less by weight of ferulic acid.

80 . The process of any one of claims 73-79 , wherein the one or more additional agents comprise:

0.5% to 2% ferulic acid; and

0.5% to 2% Pinus pinaster bark extract.

81 . The process of claim 73-80 , wherein the one or more additional agents comprise about 3% to about 10% by weight azelaic acid.

82 . The process of any one of claims 73-81 , wherein the continuous phase further comprises a lipid component.

83 . The process of claim 82 , wherein the lipid component is selected from cholesterol, ceramides, free fatty acids, and combinations thereof.

84 . The process of any one of claims 73-82 , wherein the continuous phase prevents or reduces precipitation of urea out of the emulsion composition.

85 . The process of any one of claims 73-84 , wherein the urea agent, prior to dissolving in the non-aqueous solvent, is a crystalline form of the urea agent with a particle size of about 100 m or more.

86 . The process of claim 85 , wherein suspending the dispersed phase in the continuous phase prevents or reduces recrystallization of urea from the dispersed phase.

87 . The process of claim 86 , wherein said suspending comprises suspending droplets of the dispersed phase within the continuous phase.

88 . A product produced by the process according to any one of claims 73-87 .

89 . The product of claim 88 , wherein the product is a serum.

Assignments (3)
ASSET PURCHASE AGREEMENT Recorded Apr 11, 2025
From: ICB (AN ABC), LLC
To: MF BEAUTY PARTNERS LLC
Reel/Frame 070820/0964 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2025
From: BAEK CLINICAL INC.
To: ICB (AN ABC), LLC
Reel/Frame 070781/0445 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 7, 2025
From: BAEK, JIHOON P.
To: BAEK CLINICAL INC.
Reel/Frame 070754/0942 →